Trump to Require Government to Buy American When It Comes to ‘Essential’ Drugs

August 6, 2020 by Dan McCue
Trump to Require Government to Buy American When It Comes to ‘Essential’ Drugs
President Donald Trump meets with Arizona Gov. Doug Ducey in the Oval Office of the White House in Washington, Wednesday, Aug. 5, 2020. (AP Photo/Andrew Harnik)

WASHINGTON – President Donald Trump signed an executive order Thursday requiring the federal government to buy “essential” drugs from U.S. companies, a White House trade advisor said.

“If we’ve learned anything from the China virus pandemic, it is that we are dangerously over-dependent on foreign nations for our essential medicines, for medical supplies like masks, gloves, goggles and medical equipment like ventilators,” Peter Navarro said during a conference call with reporters Thursday morning.

The president is expected to sign the order during a trip to Ohio, during which he is scheduled to deliver remarks on “economic prosperity” in Cleveland, before visiting a Whirlpool Corporation manufacturing plant in Clyde.

The order’s “buy American” provision requires the federal government to develop a list of “essential” medicines, and then requires the Defense Department, the Department of Health and Human Services, and the Department of Veterans Affairs to purchase U.S.-made versions of those drugs.

The World Health Organization already has such a list, but Navarro said more drugs are on that list than the U.S. will ever need.

The White House said the hope is that establishing a “basic level” of demand, will inspire further manufacturing investment in the U.S.

The order will also remove some of the regulations on U.S. pharmaceutical manufacturers and accelerate Food and Drug Administration and Environmental Protection Agency approval of drug manufacturing facilities in a bid to make domestic production easier, Navarro said.

Another component will combat the importation of counterfeit medicines on e-commerce platforms, he said.

“At a time when our nation’s priority should be to beat COVID-19, President Trump today signed yet another executive order that creates even more barriers to ongoing biopharmaceutical manufacturing and innovation,” said Stephen J. Ubl, president and CEO of PhRMA, which represents the country’s leading biopharmaceutical researchers and biotechnology companies.

“Companies are working around the clock to research and develop treatments and a vaccine for COVID-19. At the same time, they are working to ensure they have the capacity to manufacture the treatments and vaccines once approved so that every patient that needs them has access to them,” Ubl continued. “These efforts are all hands on deck for the biopharmaceutical industry but each executive order issued by the administration adds another roadblock, making it harder to fight this pandemic.”

The order comes as the U.S. continues to be in the grips of the coronavirus, which has infected nearly 5 million Americans and killed at least 158,268, according to Johns Hopkins University.

Early on in the outbreak, the federal government warned consumers of disruptions in the medical supply chain because so many products were made in China and elsewhere, and for a time there were dramatic shortages of some medicines, key medicine ingredients, face masks, and gloves.

Now, the administration is becoming the problem, PhRMA’s Ubl said.

“The administration is forcing biopharmaceutical companies to shift their critical attention and resources away from COVID-19 work to focus on making substantial changes to their business models necessary to comply with this and other recent executive orders,” he said. “Increasing U.S. manufacturing of medicines is a laudable goal, but it cannot happen overnight and should not come at the expense of medical innovation or Americans’ access to the medicines they need.

“The recent executive orders also contradict and undermine each other, creating chaos in an industry that is on the frontlines of fighting COVID-19,” Ubl continued. “With today’s ‘Buy American’ executive order, the administration effectively is taking the unprecedented step of mandating manufacturing of medicines in the United States. Yet at the same time, through the ‘most favored nation’ executive order, the administration is creating a huge disincentive to invest in U.S. biopharmaceutical research and manufacturing.

“Together, the result is less investment in U.S. innovation and the potential for major long-term supply chain disruptions – the opposite of what America needs right now. None of these executive orders will help patients access or afford their medicines,” he said.

“The ‘Buy American’ executive order could disrupt the global pharmaceutical supply chain, jeopardizing our ability to respond to the current crisis and potentially leading to major long-term supply chain disruptions, including shortages. Rather than government mandates, we should look for policies that enable more domestic manufacturing without putting the stability of pharmaceutical supply chains at risk,” Ubl concluded.

A+
a-

In The News

Health

Voting

Prescription Drugs

December 8, 2023
by Tom Ramstack
White House Threatens to Penalize Pharma Companies for High Prices

WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a... Read More

WASHINGTON — The Biden administration announced a plan Thursday to lower prescription drug costs in a move that takes a tough stance toward pharmaceutical companies charging high prices. If the Federal Trade Commission determines the prices are unreasonable, the new policy allows the federal government to... Read More

December 4, 2023
by Dan McCue
Justices Appear Divided Over Purdue Pharma Bankruptcy Deal

WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize... Read More

WASHINGTON — The Supreme Court appeared divided on Monday over a bankruptcy deal struck by Purdue Pharma that would immunize the Sackler family, its one-time owners, from civil lawsuits for their role in the opioid crisis.  The closely watched case is considered to be among the most... Read More

November 28, 2023
by Dan McCue
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

WASHINGTON — The Food and Drug Administration on Tuesday approved Ogsiveo tablets for adult patients with progressing desmoid tumors, a... Read More

WASHINGTON — The Food and Drug Administration on Tuesday approved Ogsiveo tablets for adult patients with progressing desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive, invading surrounding structures and organs, causing pain and disability. Although surgical... Read More

Obesity Drug Wegovy Cut Risk of Serious Heart Problems by 20%, Study Finds

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that... Read More

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients. The research is the first to document that an obesity medication can not only pare... Read More

Mind-Altering Ketamine Becomes Latest Pain Treatment, Despite Little Research

WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking... Read More

WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a trendy psychedelic therapy. Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth... Read More

November 1, 2023
by Dan McCue
FDA Approves Biosimilar for Treatment of Multiple Inflammatory Diseases

WASHINGTON — The Food and Drug Administration on Tuesday approved Wezlana, a biosimilar interchangeable with Stelara for the treatment of... Read More

WASHINGTON — The Food and Drug Administration on Tuesday approved Wezlana, a biosimilar interchangeable with Stelara for the treatment of multiple inflammatory diseases. The agency said its approval of Wezlana, which is manufactured by Amgen, was based on a comprehensive review of scientific evidence demonstrating that... Read More

News From The Well
scroll top